Clinical trialNCT02960230CompletedPhase 1/PHASE2Interventional

H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas

SponsorSabine Mueller, MD, PhDEnrollment50Diffuse Intrinsic Pontine GliomaDiffuse Midline Glioma, H3 K27M-MutantGlioma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is 3-arm, multicenter study that will be conducted through the Pacific Pediatric Neuro-oncology Consortium (PNOC). This study will assess the safety and immune activity of a synthetic peptide vaccine specific for the Histone 3 lysine27-to-methionine (H3.3K27M) epitope given in combination with poly-ICLC and the H3.3K27M epitope given in combination with poly-ICLC and the PD-1 inhibitor, nivolumab, in HLA-A2 (02:01)+ children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or other midline gliomas that are positive for H3.3K27M.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Hideho Okada, MD, PhD
University of California, San Francisco
Study Chair
clinicaltrials.gov ↗
Sabine Mueller, MD, PhD, MAS
University of California, San Francisco
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Switzerland

the University Children'S Hospital in Zurich
Zurich, Canton of Zurich, Switzerland

United States

Rady Children'S Hospital-San Diego
San Diego, California, United States
University of California, San Francisco
San Francisco, California, United States
Children'S National Medical Center
Washington D.C., District of Columbia, United States
Ann & Robert H. Lurie Children'S Hospital of Chicago
Chicago, Illinois, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Children'S Hospitals and Clinics of Minnesota
Minneapolis, Minnesota, United States
St. Louis Children'S Hospital
St Louis, Missouri, United States
Nationwide Children'S Hospital
Columbus, Ohio, United States
Oregon Health & Science University
Portland, Oregon, United States
Children'S Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
St. Jude Children'S Research Hospital
Memphis, Tennessee, United States
Texas Children'S Hospital
Houston, Texas, United States
University of Utah
Salt Lake City, Utah, United States
Seattle Children'S Hospital
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

K27M peptideNivolumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 18 Nov 2016
Primary completion: 31 Dec 2023
Completion: 31 Dec 2023
Last update posted: 22 Jan 2025
Registered enrollment: 50
Registry id: NCT02960230

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.